Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
PaperCitations, authors & open-access status
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 468 citations, 2015 year and closed oa status.
468
Citations
2015
Year
closed
OA Status